The Lynx Group

Web Exclusives

Web Exclusives — December 5, 2022
In an interview, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.
Read Article

Web Exclusives — October 19, 2021
Recently released analysis of 18F-DCFPyL PET/CT accuracy demonstrated improved diagnostic capability in men with biochemical recurrence of prostate cancer.
Read Article

Web Exclusives — October 19, 2021
NaF PET imaging study demonstrates an increased sensitivity over Tc99m-MDP bone scans for new lesion detection in patients with stable metastatic prostate cancer.
Read Article

Web Exclusives — October 19, 2021
Salvage radiotherapy decisions for patients with recurrent prostate cancer after prostatectomy change after 18F-fluciclovine PET/CT reveals higher positive findings than conventional imaging.
Read Article

Web Exclusives — October 19, 2021
Gallium-68 PSMA PET/CT imaging in patients with early relapsed prostate cancer confirms the reliability of this imaging modality in local and metastatic lesion detection.
Read Article

Web Exclusives — October 19, 2021
Recently released study results indicate whole-body MRI is superior to bone scan for prognosis in patients with metastatic hormone-naïve prostate cancer.
Read Article

Web Exclusives — September 29, 2021
The recent release of EMPIRE-1 phase 2/3 trial results indicates the use of fluorine 18 fluciclovine PET/CT to guide salvage postprostatectomy radiotherapy increases event-free survival from biochemical recurrence or persistence.
Read Article

Web Exclusives — September 29, 2021
Promising diagnostic and prognostic information with PSMA-based radioligands discussed in recently released review article.
Read Article

Web Exclusives — September 29, 2021
Investigators released participant group data from a clinical trial looking at the use of fluorine 18 fluciclovine PET/CT in men with prostate cancer and biochemical recurrence to identify potential targets for therapy.
Read Article

Web Exclusives — September 29, 2021
Updates on patient eligibility and methods from the INDICATE phase 3 trial were presented at the 2021 American Society of Clinical Oncology annual meeting.
Read Article

Page 1 of 10


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: